Elbit Imaging-M Ltd.

Foreign Filer Report • Nov 13, 2018

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2018

Commission File Number 000-28996

ELBIT IMAGING LTD.

(Translation of Registrant's Name into English)

5 SHIMSHON STREET, PETACH TIKVA, ISRAEL (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

EXHIBITS 99.1 AND 99.2 OF THIS REPORT ON FORM 6-K IS HEREBY INCORPORATED BY REFERENCE INTO ELBIT IMAGING LTD.'S REGISTRATION STATEMENT ON FORM F-1 (REGISTRATION STATEMENTS NO. 333-194519), REGISTRATION STATEMENT ON FORM F-3 (REGISTRATION STATEMENT NO. 333-172122) AND REGISTRATION STATEMENTS ON FORM S-8 (REGISTRATION STATEMENTS NOS. 333-117509, 333-130852, 333-136684 AND 333-152820), AND TO BE A PART THEREOF FROM THE DATE ON WHICH THIS REPORT IS SUBMITTED, TO THE EXTENT NOT SUPERSEDED BY DOCUMENTS OR REPORTS SUBSEQUENTLY FILED OR FURNISHED.

CONTENTS

This Report on Form 6-K of Elbit consists of the following documents, which is attached hereto and incorporated by reference herein:

• 99.1. Press Release: Elbit Imaging Ltd. announces that the CMS has updated the reimbursement code for Insightec's MRgFUS treatments
• 99.2 Summary of Insightec's financial reports (not reviewed) for the nine-month period ended on September 30, 2018

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 12, 2018 By: /s/ Ron Hadassi

ELBIT IMAGING LTD. (Registrant)

Ron Hadassi CEO and Chairman of the Board of Directors

2

ELBIT IMAGING LTD. ANNOUNCES THAT THE CMS HAS UPDATED THE REIMBURSMENT CODE FOR INSIGHTEC'S MRGFUS TREATMENTS

Tel Aviv, Israel, November 12, 2018, Elbit Imaging Ltd. (the "Company") (TASE, NASDAQ: EMITF) announced today, further to its press release dated December 14, 2017, that the Centers for Medicare and Medicaid Services (the "CMS") posted the final rule, updating the reimbursement levels for MRgFUS FDA approved indications. Effective Jan. 1, 2019, (MRgFUS in the treatment of essential tremor) will be reimbursed at USD\$12,500.50 for Medicare beneficiaries (if deemed medically appropriate). MRgFUS in the treatment of pain palliation of bone metastases will be reimbursed at USD \$10,936.00

Currently, MRgFUS for the treatment of essential tremor is covered by four of the Local Medicare Contractors. These include National Government Services (NGS) , Palmetto GBA, CGS Medicare and Wisconsin Physician Services (WPS), representing 25 States.

The Company holds approximately 75% of the share capital of Elbit Medical Technologies Ltd. (TASE: EMTC-M) (approximately 49% on a fully diluted basis) which, in turn, holds approximately 22% of the share capital in Insightec (approximately 18.5% on a fully diluted basis).

About Elbit Imaging Ltd.

Elbit Imaging Ltd. operates in the following principal fields of business: (i) Medical Industries through our indirect holdings in Insightec Ltd. and Gamida Cell Ltd.; (ii) Plots in India which are designated for sale (and which were initially designated for residential projects); (iii) Plots in Eastern Europe which are designated for sale (and which were initially designated for development of commercial centers).

For Further Information: Company Contact Ron Hadassi CEO and Chairman of the Board of Directors Tel: +972-3-608-6048 Fax: +972-3-608-6050 ron@elbitimaging.com

It is hereby clarified that this summary is published solely for the sake of caution and in light of the Company's intention to execute a Buy-Back plan of its (series I) notes.

INSIGHTEC LTD.

	September 30, 2018	December 31, 2017
		Thousands usd
Current assets	135,667	114,412
Fixed assets, net	4,356	3,230
Other long-term assets	283	172
Total Assets	140,306	117,814
Current liabilities	20,128	27,157
Long-term liabilities	1,919	926
Total Liabilities	22,047	28,083
Shareholders' equity	118,259	89,731
Total liabilities and shareholders' equity	140,306	117,814

		Nine months ended September 30,		Three months ended September 30,
	2018	2017	2018	2017
		Thousands usd
Revenues	20,351	14,840	8,140	3,967
Cost of revenues	(13,258)	(9,933)	(4,343)	(3,073)
Research and development expenses	(21,079)	(18,004)	(7,360)	(6,143)
Sales and marketing expenses	(12,942)	(11,677)	(4,331)	(3,437)
General and administrative expenses	(6,266)	(3,674)	(2,541)	(803)
Financing income, net	1,601	76	439	70
Taxes on income	(112)	(280)	0	(85)
Loss for the period	(31,705)	(28,652)	(9,996)	(9,504)